The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Thomas E. Witzig

Mayo Clinic

Stabile 628

200 First St SW



Name/email consistency: high



  • Mayo Clinic, Stabile 628, 200 First St SW, Rochester. 2005 - 2011
  • Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, USA. 1998 - 2011
  • Mayo Clinic, Rochester, MN 55905, USA. 2002 - 2009
  • Department of Internal Medicine, Division of Hematology, College of Medicine, Mayo Clinic, USA. 2007
  • Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 1999 - 2005


  1. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. Maurer, M.J., Micallef, I.N., Cerhan, J.R., Katzmann, J.A., Link, B.K., Colgan, J.P., Habermann, T.M., Inwards, D.J., Markovic, S.N., Ansell, S.M., Porrata, L.F., Johnston, P.B., Nowakowski, G.S., Thompson, C.A., Gupta, M., Syrbu, S.I., Kurtin, P.J., Macon, W.R., Nikcevich, D.A., Witzig, T.E. J. Clin. Oncol. (2011) [Pubmed]
  2. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Witzig, T.E., Reeder, C.B., LaPlant, B.R., Gupta, M., Johnston, P.B., Micallef, I.N., Porrata, L.F., Ansell, S.M., Colgan, J.P., Jacobsen, E.D., Ghobrial, I.M., Habermann, T.M. Leukemia (2011) [Pubmed]
  3. Signal transduction inhibitor therapy for lymphoma. Witzig, T.E., Gupta, M. Hematology. Am. Soc. Hematol. Educ. Program (2010) [Pubmed]
  4. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. Witzig, T.E., Wiernik, P.H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B., Vose, J.M. J. Clin. Oncol. (2009) [Pubmed]
  5. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Witzig, T.E., Geyer, S.M., Kurtin, P.J., Colgan, J.P., Inwards, D.J., Micallef, I.N., LaPlant, B.R., Michalak, J.C., Salim, M., Dalton, R.J., Moore, D.F., Reeder, C.B. Leuk. Lymphoma (2008) [Pubmed]
  6. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Witzig, T.E., Inwards, D.J., Habermann, T.M., Dogan, A., Kurtin, P.J., Gross, J.B., Ananthamurthy, A., Ristow, K.M., Garity, J.A. Mayo Clin. Proc. (2007) [Pubmed]
  7. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Witzig, T.E., Kaufmann, S.H. Curr. Treat. Options. Oncol (2006) [Pubmed]
  8. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Witzig, T.E. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  9. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Witzig, T.E., Silberstein, P.T., Loprinzi, C.L., Sloan, J.A., Novotny, P.J., Mailliard, J.A., Rowland, K.M., Alberts, S.R., Krook, J.E., Levitt, R., Morton, R.F. J. Clin. Oncol. (2005) [Pubmed]
  10. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Witzig, T.E., Vukov, A.M., Habermann, T.M., Geyer, S., Kurtin, P.J., Friedenberg, W.R., White, W.L., Chalchal, H.I., Flynn, P.J., Fitch, T.R., Welker, D.A. J. Clin. Oncol. (2005) [Pubmed]
  11. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H., Kaufmann, S.H. J. Clin. Oncol. (2005) [Pubmed]
  12. Current treatment approaches for mantle-cell lymphoma. Witzig, T.E. J. Clin. Oncol. (2005) [Pubmed]
  13. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Witzig, T.E. Drugs. Today (2004) [Pubmed]
  14. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. Garrity, M.M., Burgart, L.J., Mahoney, M.R., Windschitl, H.E., Salim, M., Wiesenfeld, M., Krook, J.E., Michalak, J.C., Goldberg, R.M., O'Connell, M.J., Furth, A.F., Sargent, D.J., Murphy, L.M., Hill, E., Riehle, D.L., Meyers, C.H., Witzig, T.E. J. Clin. Oncol. (2004) [Pubmed]
  15. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Witzig, T.E., White, C.A., Gordon, L.I., Wiseman, G.A., Emmanouilides, C., Murray, J.L., Lister, J., Multani, P.S. J. Clin. Oncol. (2003) [Pubmed]
  16. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Witzig, T.E., Bossy, B., Kimlinger, T., Roche, P.C., Ingle, J.N., Grant, C., Donohue, J., Suman, V.J., Harrington, D., Torre-Bueno, J., Bauer, K.D. Clin. Cancer Res. (2002) [Pubmed]
  17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-López, A.J., Multani, P., White, C.A. J. Clin. Oncol. (2002) [Pubmed]
  18. Heavy chain disease. Witzig, T.E., Wahner-Roedler, D.L. Curr. Treat. Options. Oncol (2002) [Pubmed]
  19. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P.S., White, C.A. J. Clin. Oncol. (2002) [Pubmed]
  20. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Witzig, T.E. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  21. A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders. Witzig, T.E., Meyers, C., Therneau, T., Greipp, P.R. Leuk. Lymphoma (2000) [Pubmed]
  22. The role of adhesion receptors in the pathogenesis of multiple myeloma. Witzig, T.E. Hematol. Oncol. Clin. North Am. (1999) [Pubmed]
  23. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma. Witzig, T.E., Camoriano, J.K., Schroeder, G., Kurtin, P.J., Habermann, T.M. Leuk. Lymphoma (1998) [Pubmed]
  24. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Witzig, T.E., Kimlinger, T., Stenson, M., Therneau, T. Leuk. Lymphoma (1998) [Pubmed]
WikiGenes - Universities